Abiopharma

LB Pharmaceuticals to Participate in Upcoming September Investor Events

(19% Negative) LB PHARMACEUTICALS INC (LBRX) Announces Business Combination

New Form 424B3 - LB PHARMACEUTICALS INC <b>Filed:</b> 2026-09-03 <b>AccNo:</b> 0001193125-26-381100 <b>Size:</b> 38 KB

(10% Negative) LB PHARMACEUTICALS INC (LBRX) Reports Q3 2026 Financial Results

LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

New Form 424B3 - LB PHARMACEUTICALS INC <b>Filed:</b> 2026-08-11 <b>AccNo:</b> 0001193125-26-343542 <b>Size:</b> 3 MB

Deep Track Biotechnology Master Fund, Ltd. 🟢 acquired 192.3K shares (2 derivative) of LB PHARMACEUTICALS INC (LBRX) at $0.00 Transaction Date: Jul 30, 2026 | Filing ID: 331058

(10% Negative) LB PHARMACEUTICALS INC (LBRX) Announces Delay in price Trials for such pre-funded warrant Due to Regulatory Process, Manufacturing Considerations, Safety Review

LB Pharmaceuticals Announces $150 Million Private Placement

New Form 424B3 - LB PHARMACEUTICALS INC <b>Filed:</b> 2026-07-29 <b>AccNo:</b> 0001193125-26-322276 <b>Size:</b> 44 KB